Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OTLK
stocks logo

OTLK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.278
-136.51%
--
--
-0.210
-129.17%
--
--
-0.190
-87.33%
Estimates Revision
The market is revising No Change the revenue expectations for Outlook Therapeutics, Inc. (OTLK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 120.32%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+120.32%
In Past 3 Month
Wall Street analysts forecast OTLK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OTLK is 4.00 USD with a low forecast of 1.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast OTLK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OTLK is 4.00 USD with a low forecast of 1.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 2.060
sliders
Low
1.00
Averages
4.00
High
8.00
Current: 2.060
sliders
Low
1.00
Averages
4.00
High
8.00
H.C. Wainwright
Douglas Tsao
NULL -> Sell
downgrade
$3 -> $1
2025-08-29
Reason
H.C. Wainwright
Douglas Tsao
Price Target
$3 -> $1
2025-08-29
downgrade
NULL -> Sell
Reason
H.C. Wainwright analyst Douglas Tsao downgraded Outlook Therapeutics with a price target of $1, down from $3. The firm is "disappointed "that the FDA issued a complete response letter for ONS-5010 in wet age-related macular degeneration. It downgraded Outlook after removing all future U.S. revenues for ONS-5010 from its valuation.
Guggenheim
Buy
to
Neutral
downgrade
2025-08-29
Reason
Guggenheim
Price Target
2025-08-29
downgrade
Buy
to
Neutral
Reason
As previously reported yesterday, Guggenheim downgraded Outlook Therapeutics to Neutral from Buy and removed the firm's price target after the company received another complete response letter from the FDA regarding their BLA resubmission for ONS-5010 for the treatment of wetAMD. The firm, which previously thought there was "a small chance of approval," now has "serious doubts" on the company's ability to get ONS-5010 approved in the U.S.
Guggenheim
Buy
to
Neutral
downgrade
2025-08-28
Reason
Guggenheim
Price Target
2025-08-28
downgrade
Buy
to
Neutral
Reason
Guggenheim downgraded Outlook Therapeutics to Neutral from Buy.
Guggenheim
Eddie Hickman
Buy
downgrade
$10 -> $8
2025-05-20
Reason
Guggenheim
Eddie Hickman
Price Target
$10 -> $8
2025-05-20
downgrade
Buy
Reason
Guggenheim analyst Eddie Hickman lowered the firm's price target on Outlook Therapeutics to $8 from $10 and keeps a Buy rating on the shares after having caught up with management following the company's Q2 earnings release. The cash position continues to be an overhang, but management is confident they have a runway to get to the Lytenava PDUFA date of August 27, the analyst tells investors.
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$33 → $24
2025-02-24
Reason
Ascendiant Capital
Edward Woo
Price Target
$33 → $24
2025-02-24
Maintains
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Hold
Maintains
$3
2025-02-18
Reason
Chardan Capital
Daniil Gataulin
Price Target
$3
2025-02-18
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Outlook Therapeutics Inc (OTLK.O) is -2.39, compared to its 5-year average forward P/E of -4.23. For a more detailed relative valuation and DCF analysis to assess Outlook Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.23
Current PE
-2.39
Overvalued PE
-1.58
Undervalued PE
-6.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
286.17
Current PS
0.00
Overvalued PS
752.43
Undervalued PS
-180.09
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OTLK News & Events

Events Timeline

(ET)
2025-11-13
08:33:39
Outlook Therapeutics reveals BLA acceptance for ONS-5010
select
2025-11-03 (ET)
2025-11-03
08:38:22
Outlook Therapeutics Refiles BLA for ONS-5010
select
2025-09-29 (ET)
2025-09-29
08:46:21
Outlook Therapeutics announces intention to resubmit BLA by the end of 2025.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-03NASDAQ.COM
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain

  • Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.

  • Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.

  • Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.

  • General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.

[object Object]
Preview
9.0
11-27NASDAQ.COM
Biotech Stocks Await FDA Verdict in December 2025

  • National Influenza Vaccination Week: Observed from December 1-5, this campaign encourages vaccination against the flu, emphasizing its safety and effectiveness, and serves as a reminder that it's never too late to get vaccinated.

  • World AIDS Day: Celebrated on December 1, this global observance raises awareness about HIV/AIDS, honors those lost, and supports those living with the virus, with a focus on political leadership and human rights to end AIDS as a public health threat by 2030.

  • HIV Statistics: In 2024, approximately 40.8 million people were living with HIV, with around 630,000 deaths from HIV-related causes and 1.3 million new infections, highlighting the ongoing impact of the epidemic.

  • Funding Concerns: There are worries about significant cuts to international HIV funding, particularly from the U.S., which has historically contributed nearly 75% of global financing, with recent reductions affecting key commitments and activities related to World AIDS Day.

[object Object]
Preview
1.0
11-24Newsfilter
Outlook Therapeutics CEO to Participate in Piper Sandler Healthcare Conference
  • Executive Participation: Outlook Therapeutics CEO Bob Jahr will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, showcasing the company's advancements in retinal disease treatment.
  • Investor Engagement: In addition to the fireside chat, management will hold one-on-one in-person meetings with qualified investors registered for the conference, enhancing communication and relationships with the investment community.
  • Live Webcast: The fireside chat will be live-streamed on the company's website under the Investors section, with a replay available for 90 days post-event, ensuring that investors who cannot attend live can still access the information.
  • Product Progress: Outlook Therapeutics is advancing the commercialization of ONS-5010/LYTENAVA™, which has received approval in Germany and the UK for treating wet AMD, and if approved in the U.S., it would be the first ophthalmic formulation of bevacizumab for retinal indications.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Outlook Therapeutics Inc (OTLK) stock price today?

The current price of OTLK is 2.06 USD — it has increased 4.57 % in the last trading day.

arrow icon

What is Outlook Therapeutics Inc (OTLK)'s business?

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

arrow icon

What is the price predicton of OTLK Stock?

Wall Street analysts forecast OTLK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OTLK is 4.00 USD with a low forecast of 1.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Outlook Therapeutics Inc (OTLK)'s revenue for the last quarter?

Outlook Therapeutics Inc revenue for the last quarter amounts to 1.51M USD, decreased % YoY.

arrow icon

What is Outlook Therapeutics Inc (OTLK)'s earnings per share (EPS) for the last quarter?

Outlook Therapeutics Inc. EPS for the last quarter amounts to -0.55 USD, decreased -131.61 % YoY.

arrow icon

What changes have occurred in the market's expectations for Outlook Therapeutics Inc (OTLK)'s fundamentals?

The market is revising No Change the revenue expectations for Outlook Therapeutics, Inc. (OTLK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 120.32%.
arrow icon

How many employees does Outlook Therapeutics Inc (OTLK). have?

Outlook Therapeutics Inc (OTLK) has 23 emplpoyees as of December 05 2025.

arrow icon

What is Outlook Therapeutics Inc (OTLK) market cap?

Today OTLK has the market capitalization of 91.50M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free